Literature DB >> 27782325

Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Daniel Ricklin1, Edimara S Reis2, Dimitrios C Mastellos2,3, Piet Gros4, John D Lambris5.   

Abstract

As a preformed defense system, complement faces a delicate challenge in providing an immediate, forceful response to pathogens even at first encounter, while sparing host cells in the process. For this purpose, it engages a tightly regulated network of plasma proteins, cell surface receptors, and regulators. Complement component C3 plays a particularly versatile role in this process by keeping the cascade alert, acting as a point of convergence of activation pathways, fueling the amplification of the complement response, exerting direct effector functions, and helping to coordinate downstream immune responses. In recent years, it has become evident that nature engages the power of C3 not only to clear pathogens but also for a variety of homeostatic processes ranging from tissue regeneration and synapse pruning to clearing debris and controlling tumor cell progression. At the same time, its central position in immune surveillance makes C3 a target for microbial immune evasion and, if improperly engaged, a trigger point for various clinical conditions. In our review, we look at the versatile roles and evolutionary journey of C3, discuss new insights into the molecular basis for C3 function, provide examples of disease involvement, and summarize the emerging potential of C3 as a therapeutic target.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  compstatin; convertase; immune evasion; inflammation; therapeutics

Mesh:

Substances:

Year:  2016        PMID: 27782325      PMCID: PMC5427221          DOI: 10.1111/imr.12500

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  229 in total

1.  Characterization of a C3a receptor in rainbow trout and Xenopus: the first identification of C3a receptors in nonmammalian species.

Authors:  Hani Boshra; Tiehui Wang; Leif Hove-Madsen; John Hansen; Jun Li; Anjun Matlapudi; Christopher J Secombes; Lluis Tort; J Oriol Sunyer
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

Review 2.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

3.  A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family.

Authors:  Daniel Ricklin; Apostolia Tzekou; Brandon L Garcia; Michal Hammel; William J McWhorter; Georgia Sfyroera; You-Qiang Wu; V Michael Holers; Andrew P Herbert; Paul N Barlow; Brian V Geisbrecht; John D Lambris
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

4.  Comprehensive Analysis of Complement Genes in Patients with Atypical Hemolytic Uremic Syndrome.

Authors:  Tao Zhang; Jianping Lu; Shaoshan Liang; Dachen Chen; Haitao Zhang; Caihong Zeng; Zhihong Liu; Huimei Chen
Journal:  Am J Nephrol       Date:  2016-04-12       Impact factor: 3.754

Review 5.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

6.  Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.

Authors:  Eva Torreira; Agustín Tortajada; Tamara Montes; Santiago Rodríguez de Córdoba; Oscar Llorca
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

7.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

8.  Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.

Authors:  Marie Frimat; Fanny Tabarin; Jordan D Dimitrov; Caroline Poitou; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi; Lubka T Roumenina
Journal:  Blood       Date:  2013-05-21       Impact factor: 22.113

Review 9.  Complement in immune and inflammatory disorders: therapeutic interventions.

Authors:  Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-15       Impact factor: 5.422

10.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Authors:  Paraskevas Iatropoulos; Marina Noris; Caterina Mele; Rossella Piras; Elisabetta Valoti; Elena Bresin; Manuela Curreri; Elena Mondo; Anna Zito; Sara Gamba; Serena Bettoni; Luisa Murer; Veronique Fremeaux-Bacchi; Marina Vivarelli; Francesco Emma; Erica Daina; Giuseppe Remuzzi
Journal:  Mol Immunol       Date:  2016-02-16       Impact factor: 4.407

View more
  116 in total

1.  Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma.

Authors:  Alejandra Bosco; Sarah R Anderson; Kevin T Breen; Cesar O Romero; Michael R Steele; Vince A Chiodo; Sanford L Boye; William W Hauswirth; Stephen Tomlinson; Monica L Vetter
Journal:  Mol Ther       Date:  2018-08-24       Impact factor: 11.454

2.  Safety profile after prolonged C3 inhibition.

Authors:  Edimara S Reis; Nadja Berger; Xin Wang; Sophia Koutsogiannaki; Robert K Doot; Justin T Gumas; Periklis G Foukas; Ranillo R G Resuello; Joel V Tuplano; David Kukis; Alice F Tarantal; Anthony J Young; Tetsuhiro Kajikawa; Athena M Soulika; Dimitrios C Mastellos; Despina Yancopoulou; Ali-Reza Biglarnia; Markus Huber-Lang; George Hajishengallis; Bo Nilsson; John D Lambris
Journal:  Clin Immunol       Date:  2018-10-10       Impact factor: 3.969

3.  Discovery and Design of First Benzylamine-Based Ligands Binding to an Unlocked Conformation of the Complement Factor D.

Authors:  Anna Vulpetti; Nils Ostermann; Stefan Randl; Taeyoung Yoon; Aengus Mac Sweeney; Frederic Cumin; Edwige Lorthiois; Simon Rüdisser; Paul Erbel; Jürgen Maibaum
Journal:  ACS Med Chem Lett       Date:  2018-04-24       Impact factor: 4.345

4.  Factor H: a novel modulator in sickle cell disease.

Authors:  Wassim El Nemer; Bérengère Koehl
Journal:  Haematologica       Date:  2019-05       Impact factor: 9.941

5.  Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B.

Authors:  Xin Xu; Chi Zhang; Dalton T Denton; Daniel O'Connell; Daniel W Drolet; Brian V Geisbrecht
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.422

Review 6.  Production of complement components by cells of the immune system.

Authors:  R Lubbers; M F van Essen; C van Kooten; L A Trouw
Journal:  Clin Exp Immunol       Date:  2017-03-24       Impact factor: 4.330

Review 7.  Novel mechanisms and functions of complement.

Authors:  George Hajishengallis; Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Immunol       Date:  2017-11-16       Impact factor: 25.606

8.  A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement.

Authors:  Rasmus K Jensen; Rasmus Pihl; Trine A F Gadeberg; Jan K Jensen; Kasper R Andersen; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2018-03-01       Impact factor: 5.157

Review 9.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

10.  Analysis of complement deposition and processing on Chlamydia trachomatis.

Authors:  Mads Lausen; Mikkel Eggert Thomsen; Gunna Christiansen; Nichlas Karred; Allan Stensballe; Tue Bjerg Bennike; Svend Birkelund
Journal:  Med Microbiol Immunol       Date:  2020-11-18       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.